US66987V1098 - ADR
NOVARTIS AG-SPONSORED ADR
NYSE:NVS (4/26/2024, 11:12:10 AM)
97.84
-1.22 (-1.23%)
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 101,703 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
NOVARTIS AG-SPONSORED ADR
Lichtstrasse 35
Basel BASEL-STADT CH 4056
P: 41613241111
CEO: Vasant (Vas) Narasimhan
Employees: 101703
Website: https://www.novartis.com/
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
A double beat on the latest quarterly results and raised guidance made investors happy.
A double beat on the latest quarterly results and raised guidance made investors happy.
NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
NVS earnings call for the period ending March 31, 2024.
During the Investing Club's Morning Meeting, Jim Cramer offered his thoughts on recent earnings from RTX, PepsiCo, Nucor, Novartis and Cadence Design Systems.
Here you can normally see the latest stock twits on NVS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: